This meta-analysis provides comprehensive evidence supporting the efficacy and safety of IL-23p19 inhibitors—namely mirikizumab, guselkumab, and risankizumab—in the treatment of moderate to severe ulcerative colitis (UC). This evidence concerns the gene IL23A and ulcerative colitis.